Fri, Nov 28, 2014, 7:27 AM EST - U.S. Markets open in 2 hrs 3 mins

Recent

% | $
Quotes you view appear here for quick access.

Response Genetics, Inc Message Board

  • frankfrazzano frankfrazzano Dec 22, 2009 8:46 AM Flag

    Why I am long RGDX......

    -I went into RGDX back in 2008 buying very cheap shares(~8000) and rode them up into the summer of 2009 and sold all for a nice profit! Round trip 1 was a good $ success as I did my homework early on!

    -I bought back into RGDX for a second round~ October 2009, when Landsdowne Partners announced they would dissolve their 3M share position. My thinking was this dissolution would put some selective pressure on the entry price and I could offer a low bid to ask and start accumulating again. I have completed that accumulation and now hold 11,967 shares at 1.01/share cost net net. I started to buy down at ~ 1.50/share very slowly! My current net net includes round 1 success!

    -Yesterday on another Board(AMAG) I announced to my friends this Diagnostic Play.These are people who do strong DD, are Bio investors with substantial buying power who know me and my MO! They know when they see a growth opportunity. When they do their DD they will buy this company and this board will start to clammour! By than it will be moving up quite fast and the GREEN will stick out like a sore thumb!This is FYI to all who are watching RGDX. This is your heads up! This is no pump and dump! Stankovich buying 7000 shares 12/10 CFO means he knows the numbers as an insider!

    -I expect RGDX to announce very strong Q-4 Revenues ~ 2/15/2010...that will be 3 consecutive quarters of advancing revenues predicated on a fast growing number of tests performed and improved medicare/private payor reimburements. It will include the backlog of tests from Taiho/GSK? which were delayed! It will include the new Gastric Ca test!It will include higher Medicare reimbursements!

    -Tests run rate Q-1,Q-2 and Q-3(2009)were 800 tests, 1250 tests and 1800 tests run. That is pure and simple great growth for a company w/ 10 sales reps accross the US!

    -Reimburements on those test have increased dramatically as high as $2000/test due to added gene probes and drug assays such as pemetrexed(Alimta-LLY) used 1st line in NSCLC these days!

    -That means any patient w/ a diagnosis of NSCLC who is a candidate for Alimta will most likely be required by the PAYOR to have a confirmatory test run! These drugs are simply too toxic/expensive not to know for sure up front what to expect!

    -In Lung Ca the Response Diagnostic is the only test available to run ERCC1,RRM1,EGFR,and KRAS genes which are prognostic bio markers the NCCN 2009 practice guidelines call upon!

    -This is a dream $$$ opportunity because the company can just "Bolt On" new assays to an existing panel which has ~ slots/wells and test a new drug. They increase revs dramatically w/ minimal new costs of tests!

    -Currently the FDA requires tests for drugs such as Roche/DNA Herceptin(traztuzumab) and BMY/LLY Erbitux(cetuximab) and Sprycel(Dasatinib). We can expect this list to grow rapidly in 2010 and on as newer agents become approved at near light speed. Cost alone will drive this growth.

    -Allos(ALTH) has announced their new ca drug Folotyn will cost up to $30,000/month. Insurers have declared fowl but admit they will pay for it. Testing will be required on Folotyn guaranteed!!

    -In the EU there are now 11 drugs screened including Tasigna(nilotinib)by NVS.

    -This company plays ball on both sides of the fense. They sell theses tests to big pharma like Roche,GSK,LLY to enrich the study data and to the doctor in the field to enrich the prognosis! Its just plain simple a winning approach!

    -Insider own 58% and Institutions own 35% but Landsdowne is still unloading as an institution and I do not see any significant New players yet. This is because RGDX is flying under the radar and they are so tiny! This will not last for long!

    -Lung/CRC alone market potential is for 360,000 tests or $550M yearly and RGDX just got these tests out in the last year on the market. Barely scratched the surface!

    Sorry I was so long winded but I wanted my first new post to have some meat for those newly interested!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You got a big mouth, fella. Everything you say carries at least one exclamation point! Who are you shouting at?

      Now, big mouth, show us all on the chart where you bought and then "rode it up." You just barely eked out a tiny profit if any at all in August, maybe, but I doubt it, after sitting on a loser for seven months at least.

      You're disgusting. C'mon, SHOW us - on the graph, give us the dates and prices of your victories - or SHUT UP! Anything at all that is consistent with your claims and that showed a profit would be unbelievable on the chart. And I don't believe you one bit.

    • You "rode them up?" RGDX started 2008 at 7 and steadily declined all year in a nearly monotonic descent to about 1.40. You rode those shares DOWN, buddy. Maybe you bought them at the very end of 08; if so then you sat there even for 9 months until you had a day at the beginning of August ("summer") to sell, momentarily, for a little over 2. Evidently that's when you took your "nice profit." Look at the graph, people:
      http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=rgdx&sid=0&o_symb=rgdx&freq=2&time=20

      You're full of it. How many shares are you trying to pump right now for another "nice profit?" I would never mess around with a stock of such low volume. If it is going to go to 100, great, I'll buy at 10 or 15 when there's some volume.

      • 1 Reply to azit_whir
      • ok you POS here it is because I have followers so I do it for them and not your dumb azz azit twit!this is in my taxable account for 2009..add up the sales MFr


        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/23/2009
        100.000
        $134.99
        $130.00
        $4.99
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/23/2009
        100.000
        $134.99
        $125.00
        $9.99
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/23/2009
        100.000
        $135.00
        $125.00
        $10.00
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/29/2009
        400.000
        $560.02
        $440.00
        $120.02
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/29/2009
        500.000
        $689.99
        $505.00
        $184.99
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/29/2009
        100.000
        $140.01
        $110.00
        $30.01
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/29/2009
        400.000
        $551.97
        $404.00
        $147.97
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/31/2009
        100.000
        $140.00
        $101.00
        $39.00
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/31/2009
        20.000
        $28.20
        $19.00
        $9.20
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/31/2009
        400.000
        $559.98
        $380.00
        $179.98
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/31/2009
        380.000
        $535.78
        $361.00
        $174.78
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        07/31/2009
        100.000
        $141.00
        $95.00
        $46.00
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        08/04/2009
        200.000
        $281.99
        $190.00
        $91.99
        RESPONSE GENETICS INC COM CUSIP: 76123U105
        Date Sold
        Qty
        Proceeds
        Cost Basis
        Gain/Loss
        08/04/2009
        300.000
        $422.99
        $285.00
        $137.99


        cont'

    • thanx collelungo..for your insight...I am doing my DD on all your picks including CLRT...what did u think of my analysis on ROSG vs RGDX...does the sales revs in your opinion relative to MC impact your investment thesis?

      EXAS is a putaway for me now...im in at .51 so I think I am pretty risk free on that one...I wish I had 11,000 shares instead of 1100!

      frank

    • thanks for the info on SQNM and EXAS. Looked at EXAS a while back and didn't like their narrow focus and didn't think they could develop a platform for multiple tests, which is what I think will be the winning theme. It seems to be working for them!
      RGDX has the same potential as EXAS as far as equity appreciation, IMO.
      Haven't heard anything about the relationship except for what I read in releases and the link you provided (thanks BTW. Seems to be a weak attempt at PR campaign to strong arm RGDX into entering into negotiations to restructure deal, which I believe Neo doesn't have much leverage.

      Partnerships and JV's are going to be very important in this "land grab" phase, IMO. You are who you are with. NGNM having ABT on their team is a huge benefit to them. They need to strengthen their sales organization immediately.

      Take a look at CLRT. Great story there. Do your own DD but the message board is second to none, IMO. CLRT has a lot going for it and will be a big winner in this space, again IMO.

    • <I doubt that RGDX turns profitable in 2010, but it will happen.>

      cali grl at what run rate of kits do you believe they break even or start to turn profit....currently RGDX runs about 1800 kits per quarter?

      anyone? why?

      frank

    • maybe you get a better chance today or tomorrow...they ROSG report the great JHU news and the stock pops to 3.09...classic SELL THE NEWS and buy back latter stock IMO, since now they announce new DEBT of $5M!

      I am looking at them again as I write...we may be able to pick up shares now < 2...

      <Rosetta Genomics (ROSG Quote) should open nearly 30% lower after the company said late Wednesday that it would raise $5.1 million in a registered direct offering of units consisting of one ordinary share and a warrant to purchase one half of an ordinary share for a purchase price of $2. The 50-day average daily volume for Rosetta Genomics is 47,000, according to the Nasdaq. The stock had jumped 67% to $3.09 during Wednesday's session before details of the offering were announced.>

      glta

      frank

    • I am long it

    • colle... I have been watching them for two years! I have always felt Rosetta was a better play than SQNM but opted for RGDX when I considered who was in my strategy best going forward! I also like EXAS in CRCa testing!

      I know people in ROSG who bought at 5 and still have conviction here at 3! I liked it at 2 recently but went 100% RGDX because I think they are the best play going forward!

      frank

      what do you hear on the NEO-RGDX relationship w/ KRAS panels?

    • wish I owned this one today...

      http://finance.yahoo.com/q?s=rosg

      This shows the potential home run nature of these companies. IMO

    • good post overall but with all due respect calif grl... I read your post perfectly... and in the ST it hit 1.59 high today and has held 1.50 all day,....how do you figure a new yearly high bodes not too well in the "short term"?

      The market seems to be saying yes to RGDX! I too want answers on the "relationship" going forward!

      who said they RGDX were replacing NGNM salepeople w/ new hires at RGDX. The way I interpreted recent articles from both companies...it sounded as if they plan to cont.working together!

      Dannenberg did not reference a change in the relationship although the NEO CEO Van Ort seemed to not be happy w/ his own saleforce productivity....recently saying,

      "it is not at an acceptable level"!

      http://www.genomeweb.com/blog/has-response-genetics-lost-its-kras-mojo-neogenomics-thinks-so?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+genomeweb+%28GenomeWeb+%C3%9Cberfeed%29

      RGDX seems to be clueless as to why the KRAS panels are not as profitable to NEO...NEO raved about them early on in 2008. I do not know what to make of this! Why does NEO realize the 1.1M loss...I'm confused and admit I do not understand the Relationship to begin with!

      please correct me w/ a link if you know whats really going on here!

      I appreciate your perspective...do you work in this field?

      I am retired US pharma 33 years...Bio-pharma investor today!

      frank

    • View More Messages
 
RGDX
0.492+0.0020(+0.41%)Nov 26 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.